HOME >> BIOLOGY >> NEWS
Small-molecule inhibitors of anthrax lethal factor identified

Scientists have identified several compounds that block the activity of a key anthrax protein called lethal factor (LF)--an important first step in developing therapeutics to counter the disease.

Anthrax, a disease caused by the spore-forming bacterium Bacillus anthracis, is most deadly when exposure occurs through inhalation. Prompt diagnosis and antibiotic treatment during the early stages of infection are critical. In many cases, however, antibiotics may not be effective--particularly when bacterial overload causes large amounts of anthrax toxin to be released in the body.

Anthrax toxin consists of three proteins: lethal factor, protective antigen, and edema factor, all of which work in concert to kill host cells. While the exact mechanism of anthrax toxin is not yet well understood, it is clear that developing methods to inhibit toxin assembly and/or function is critically important.

In an article published in this month's issue of Nature Structural and Molecular Biology, investigators from the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), the National Cancer Institute (NCI), the Burnham Institute, and the Harvard Institutes of Medicine report using a high-throughput assay to screen a group of 1,990 compounds known as the NCI diversity set. The molecular properties of this group are predictive of a larger set of more than 100,000 compounds.

Using a two-stage screening assay, the team identified a number of compounds that inhibited the activity of LF. All inhibitors were further verified by high-performance liquid chromatography and their efficacy was validated in cell culture. Finally, molecular modeling techniques were used to predict structural features that contribute to inhibitor binding and potency.

These techniques revealed a common pharmacophore--a "scaffold" upon which future therapeutics can be built. This pharmacophore will serve as a basis for directing future effo
'"/>

Contact: Caree Vander Linden
Caree.Vander-Linden@amedd.army.mil
301-619-2285
US Army Medical Research Institute of Infectious Diseases
22-Jan-2004


Page: 1 2

Related biology news :

1. Small-molecule inhibitors of botulinum neurotoxin identified
2. Chemical genetics identifies SARS inhibitors
3. COX-2 inhibitors and renal damage in obesity-related Type II diabetes
4. Researchers learn certain enzyme inhibitors may help in cancer therapy following initial procedures
5. Study offers new insights into angiogenesis inhibitors
6. COX-2 inhibitors may delay onset of breast cancer
7. Harvard Medical School researchers discover first in a new class of mitosis inhibitors
8. Researchers improve detection of diverse anthrax strains
9. Argonne scientists determine structure of staph, anthrax enzyme
10. Crystal structure for anthrax-cell binding complex
11. TIGR president discusses significance of finding anthrax toxin

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/19/2019)... ... August 19, 2019 , ... Since ... use of ultra-thin two dimensional slices which are placed on microscope slides, stained ... complex tissues and complicated features such as vasculature and thus researchers in the ...
(Date:8/15/2019)... ... ... Deep Science Ventures (DSV), a new paradigm for applied science, today announced ... 100 companies over the next 10 years to address the urgent need for new ... was founded to create a better method for launching science companies; one that takes ...
(Date:8/15/2019)... ... , ... Serialization deadlines in the US and European Union ... becomes fully applied in the United States in 2023, pharmaceutical companies are scrutinizing ... most regulations?including the Drug Supply Chain Security Act (DSCSA)?have required minimal system capabilities. ...
Breaking Biology News(10 mins):
(Date:7/9/2019)... ... July 08, 2019 , ... Today, at the BIO World Congress ... Association (NCGA) announced the winners of the Consider Corn Challenge II. Three winners ... field corn to produce biobased materials. , “Corn is a sustainable, abundant and ...
(Date:6/18/2019)... ... ... Personalized Stem Cells, Inc (“PSC”), a human adipose-derived stem cell ... of a person’s own adipose-derived stem cells to treat their osteoarthritis. The first clinical ... IND is the first of several planned clinical trials which will enable qualified PSC-enrolled ...
(Date:6/11/2019)... and ROANOKE, Va. (PRWEB) , ... June 11, ... ... optimized for microlearning engagement, and Carilion Clinic, a national leader in opioid treatment, ... latest in virtual care. , Mytonomy recently deployed its virtual care ...
(Date:5/31/2019)... ... May 29, 2019 , ... ... providing proprietary interest to our methodology, processes, and diagnostic techniques. The patent ... extends Somnology’s IP rights including our proprietary sleep scoring methodology. The approval ...
Breaking Biology Technology:
Cached News: